Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Ruxolitinib Oral Tablet [Jakafi]
DRUG
2 trials
Sponsors
Oncotherapeutics
Conditions
Multiple Myeloma
Early Phase 1
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Recruiting
NCT06209606
Oncotherapeutics
Multiple Myeloma
Start: 2022-12-08
End: 2029-02-28
Target: 30
Updated: 2024-12-17
Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Recruiting
NCT03110822
Oncotherapeutics
Multiple Myeloma
Start: 2017-02-01
End: 2027-02-28
Target: 134
Updated: 2023-11-01
Related Papers
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
2024-04-20
2 citations
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients
Hematological Oncology
2022-08-10
9 citations
Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma
Blood
2021-11-05
1 citations
Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Blood
2020-11-05
2 citations
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research
2020-01-14
35 citations
A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM).
Journal of Clinical Oncology
2019-05-20
1 citations
A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients.
Journal of Clinical Oncology
2018-05-20
4 citations